Pharmaceutical

Mission Therapeutics forges ahead with Phase II study for DUB inhibitor 

A Phase II clinical trial treating 160 acute kidney injury patients with MTX652 is expected to be initiated in Q1 2024.

Dec 14, 2023 - 18:00
Mission Therapeutics forges ahead with Phase II study for DUB inhibitor 
A Phase II clinical trial treating 160 acute kidney injury patients with MTX652 is expected to be initiated in Q1 2024.
Read the original article

Tags:

Previous Article

Novo Nordisk acquires Alkermes’s Irish plant to expand manufacturing capacity

Next Article

Eight evolving patient communication risks in pharma and biotech

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: UnitedHealth’s profit jumps as medical costs come in lower than expected

STAT+: UnitedHealth’s profit jumps as medical costs com...

Oct 14, 2023

Risk adjusted net present value: What is the current va...

Jul 2, 2024

Grifols gears up for FDA approval of fibrinogen replacement therapy

Grifols gears up for FDA approval of fibrinogen replace...

Feb 14, 2024